OakChart

Shattuck Labs Inc

STTKHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:20 PM ET

4.93+0.08 (1.74%)
2026-11-11 21:20 CET
Market cap
493.94 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-67.72 USD m
Free cash flow, TTM
-49.76 USD m
EPS diluted, TTM
-0.51
P/E
-
Compare

Price

STTK against its 20, 50 and 200-day averages
2050200miss
4.006.008.006.2M12.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26STTKclose 4.9420-day 5.3550-day 5.88200-day 6.064.9452w high

40.8% under the 52-week high of 8.33 on 20 Apr 2026. 52-week low 1.72 on 14 Nov 2025. Last 15 sessions, 35.8% high to low

Volume 0.49× normal · the line is the 50-bar volume average

Profile

STTK
52-week range, 49% of the way up
1.728.33

Shattuck Labs, Inc. is a clinical-stage biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. It focuses on developing a potential first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.

IndexRUT
Employees40
IPOOct 09, 2020
Beta1.15
ATR, 14d0.41
Rel volume0.49
Short float12.28%
Insider own14.10%
Inst own71.88%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap502.56M
Enterprise Value308.70M
Income-67.72M
Sales0.00M
Book/sh1.90
Cash/sh1.93
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees40
IPOOct 09, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.59
P/C2.56
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio15.80
Current Ratio15.80
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.51
EPS next Y-0.53
EPS next Q-0.14
EPS this Y28.38%
EPS next Y-5.13%
EPS next 5Y6.00%
EPS past 3/5Y33.69% 4.36%
Sales past 3/5Y15.32% -36.82%
EPS Y/Y TTM50.26%
Sales Y/Y TTM-100.00%
EPS Q/Q1.22%
Sales Q/Q-100.00%
EarningsNov 05 BMO
EPS/Sales Surpr.-33.08% -100.00%

Ownership

Insider Own14.10%
Insider Trans-0.16%
Inst Own71.88%
Inst Trans26.39%
ROA-43.93%
ROE-47.20%
ROIC-34.69%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-7.81%
SMA50-16.10%
SMA200-18.60%
Trades-

Technical

Shs Outstand101.83M
Shs Float87.49M
Short Float12.28%
Short Ratio9.41
Short Interest10.75M
52W High8.33 -40.76%
52W Low1.72 186.90%
Volatility10.84% 7.65%
ATR (14)0.41
RSI (14)40.39
Beta1.15
Rel Volume0.49
Avg Volume1.14M
Volume509,967

Performance

Perf Week-4.18%
Perf Month-10.12%
Perf Quarter-32.59%
Perf Half Y-26.89%
Perf YTD35.19%
Perf Year149.22%
Perf 3Y168.18%
Perf 5Y-62.33%
Perf 10Y-
Recom1.00
Target Price16.38
Prev Close4.85
Price4.93
Change %1.74%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 12, 2026InitiatedUUBSBuy$17+244.5%
Aug 24, 2026InitiatedRRaymond JamesStrong Buy$18+264.8%
Jul 20, 2026InitiatedLLeerink PartnersOutperform$16+224.2%
Apr 27, 2026InitiatedCCantor FitzgeraldOverweight
Mar 06, 2026ResumedNNeedhamBuy$25+406.6%
Jan 28, 2026InitiatedPPiper SandlerOverweight$15+204.0%
Dec 01, 2025UpgradeHH.C. WainwrightNeutral → Buy$6+21.6%
Sep 08, 2025InitiatedWWedbushOutperform$4-18.9%
Mar 17, 2025InitiatedLLeerink PartnersOutperform$4-18.9%
Oct 02, 2024DowngradeNNeedhamBuy → Hold

Peers

Mkt cap
TickerCompanyMkt cap
SYRESpyre Therapeutics Inc10.10B
ROIVRoivant Sciences Ltd30.42B
AGMBAgomAb Therapeutics NV ADR343.27M
ODTXOdyssey Therapeutics Inc982.51M
MLTXMoonLake Immunotherapeutics1.16B
ABVXAbivax ADR8.03B
MRKMerck & Co Inc361.59B
PTGXProtagonist Therapeutics Inc8.76B
TEVATeva- Pharmaceutical Industries Ltd50.12B
SNYSanofi ADR115.16B

Insider trading

latest 14 of 17
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Shukla Abhinav A.Chief Technical OfficerJul 06 '26Option Exercise3.5712,15343,38698,533Jul 07 07:00 PM
Shukla Abhinav A.Chief Technical OfficerJul 02 '26Option Exercise3.574101,46486,790Jul 07 07:00 PM
Shukla Abhinav A.Chief Technical OfficerJul 02 '26Sale7.014102,87486,380Jul 07 07:00 PM
Shukla Abhinav A.Chief Technical OfficerJun 30 '26Option Exercise3.5723,36583,413109,745Jul 02 08:17 PM
Shukla Abhinav A.Chief Technical OfficerJul 01 '26Option Exercise3.5710035786,480Jul 02 08:17 PM
Shukla Abhinav A.Chief Technical OfficerJun 30 '26Sale7.0823,365165,42486,380Jul 02 08:17 PM
Shukla Abhinav A.Chief Technical OfficerJul 01 '26Sale7.0710070786,380Jul 02 08:17 PM
Pandite Arundathy N.Chief Medical OfficerJun 30 '26Sale7.0130,000210,300136,219Jul 02 08:15 PM
Shukla Abhinav A.OfficerJul 02 '26Proposed Sale7.014102,874Jul 02 04:24 PM
Shukla Abhinav A.OfficerJul 01 '26Proposed Sale7.07100707Jul 01 04:19 PM
Shukla Abhinav A.OfficerJun 30 '26Proposed Sale7.0823,365165,469Jun 30 04:10 PM
SIEGALL CLAY BDirectorJun 09 '26Buy4.0062,500250,000318,608Jun 11 05:00 PM
Shukla Abhinav A.Chief Technical OfficerMay 12 '26Option Exercise3.572,0327,25483,290May 14 08:05 PM
Shukla Abhinav A.Chief Technical OfficerMay 12 '26Sale7.012,03214,24481,258May 14 08:05 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VHTVanguard Health Care ETFAUM: 21.51B
VFMOVanguard U.S. Momentum Factor ETFAUM: 1.82B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 194
  • Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) -12.82%
  • Shattuck Labs Announces Two Poster Presentations at UEG Week 2026 (GlobeNewswire) -9.85%
  • Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development (GlobeNewswire)
  • Shattuck Labs Announces Participation in Upcoming September Investor Conferences (GlobeNewswire)
  • Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
  • SpaceX initiated, PayPal upgraded: Wall Street's top analyst calls (The Fly)
  • Netflix upgraded, Microsoft initiated: Wall Street's top analyst calls (The Fly) -9.43%
  • Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering (GlobeNewswire)
  • Shattuck Labs, Inc. Announces Proposed Public Offering (GlobeNewswire) +9.49%
  • Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update (GlobeNewswire)
  • Shattuck Labs Announces Phase 1 Results for SL-325 (GlobeNewswire) -14.85%
  • Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8 (GlobeNewswire)
  • Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) -6.29%
  • Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +7.82%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.140-0.105-0.1400.000.0311
2026Q22026-08-11-0.120-0.124-0.1170.000.009
2026Q12026-05-07-0.130-0.139-0.1320.000.007
2025Q42026-03-05-0.120-0.136-0.1210.000.256
2025Q32025-11-06-0.140-0.149-0.1391.000.006
2025Q22025-08-14-0.240-0.245-0.2440.000.004
2025Q12025-05-01-0.270-0.281-0.2690.000.004
2024Q42025-03-27-0.370-0.319-0.3670.000.805
2024Q32024-11-14-0.330-0.417-0.3283.000.654
2024Q22024-08-01-0.420-0.414-0.4241.610.505
2024Q12024-05-02-0.370-0.448-0.3661.120.305
2023Q42024-02-29-0.410-0.568-0.4110.710.345
2023Q32023-11-09-0.650-0.519-0.6480.690.226
2023Q22023-08-10-0.500-0.517-0.5030.200.185
2023Q12023-05-09-0.490-0.629-0.4880.060.175
2022Q42023-02-23-0.600-0.630-0.5990.390.055

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-2.360-1.894-0.8769.9310.00
2021FY-1.070-1.703-1.07030.002.26
2022FY-2.410-2.421-2.4060.650.25
2023FY-2.050-2.203-2.0491.661.15
2024FY-1.490-1.446-1.4865.726.51
2025FY-0.700-0.768-0.7001.001.17
2026FY--0.501--0.10
2027FY--0.527--0.10
2028FY--0.581--0.20
2029FY--0.652--0.60
2030FY--0.856--0.65

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-059100.120.001.10
2026Q4S2026-10-099000.090.000.80
2026Q4S2026-08-208000.100.000.80
2026Q4S2026-08-117000.000.000.00
2026Q4S2026-07-237000.000.000.00
2026Q4S2026-07-176000.000.000.00
2026Q4S2026-05-075000.000.000.00
2026Q4S2026-04-245000.000.000.00
2026Q4S2026-03-124000.000.000.00
2026Q4S2026-03-053000.000.000.00
2026Q4S2026-01-262000.000.000.00
2026Q4S2025-11-121000.000.000.00
2026Q4S2025-11-112000.000.000.00
2026Q4S2025-11-102000.000.000.00

Estimate history

EPS, annual-0.177-0.575-0.876-1.07-2.406-2.049-1.486-0.701-0.5072
Period20182019202020212022202320242025TTM
EPS, quarterly-0.328-0.367-0.269-0.244-0.139-0.121-0.132-0.117-0.138
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual22.4429.8879.93430.0170.6521.6575.72110
Period20182019202020212022202320242025TTM
Sales, quarterly2.99700010000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual41.74441.74441.76742.33942.39147.2647.71563.28101.833
Period20182019202020212022202320242025MRQ
Shares, quarterly47.7447.71547.89947.90363.15263.2875.582100.726101.833
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.001.005.721.660.6530.029.939.8922.44
Cost of Goods Sold Incl. D&A3.463.693.834.043.381.38---
Gross Profit-3.46-2.691.89-2.38-2.7228.64---
Selling, General and Administrative Excl. Other68.5848.8482.2489.57100.6173.9146.2534.4228.34
Research and Development49.8431.6966.9974.3182.9056.5637.4829.2224.81
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-72.04-51.53-80.34-91.96-103.33-45.27-36.93-25.07-6.15
Interest Expense0.000.000.000.000.000.000.000.002.63
Unusual Expense0.08-0.020.220.000.000.000.000.00-0.78
Net Income Before Taxes-67.72-48.81-75.41-87.30-101.94-44.97-36.60-23.98-7.39
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-67.72-48.81-75.41-87.30-101.94-44.97-36.60-23.98-7.39
Net Income From Continuing Operations-67.72-48.81-75.41-87.30-101.94-44.97-36.60-23.98-7.39
Net Income-67.72-48.81-75.41-87.30-101.94-44.97-36.60-23.98-7.39
EPS (Recurring)-0.37-0.70-1.48-2.05-2.41-1.07-0.88-0.57-0.19
EPS (Basic, Before Extraordinaries)-0.51-0.70-1.49-2.05-2.41-1.07-0.88-0.57-0.18
EPS (Diluted)-0.51-0.70-1.49-2.05-2.41-1.07-0.88-0.57-0.18
EBITDA-68.58-47.84-76.52-87.92-99.95-43.89-36.31-24.53-5.89
Non-Operating Income (Expense)4.402.705.164.661.380.290.331.080.61
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense10.057.009.556.946.465.471.270.460.42
Price To Sales Ratio-253.9910.74183.31149.5011.92220.36--
Gross Margin--268.8033.07-143.93-417.6495.40---
Operating Margin--5,153.20-1,404.39-5,549.61-15,848.01-150.81-371.76-253.53-27.40
Net Margin--4,880.90-1,318.13-5,268.44-15,635.74-149.83-368.46-242.56-32.92
Shares Outstanding101.8363.2847.7147.2642.3942.3441.7741.7441.74
Market Capitalization493.94493.9457.77336.0897.50359.522,187.812,212.44-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.001.000.000.000.00
Cost of Goods Sold Incl. D&A0.810.850.890.910.920.930.940.94
Gross Profit-0.81-0.85-0.89-0.910.08-0.93-0.94-0.94
Selling, General and Administrative Excl. Other26.2315.3014.6512.3810.8012.1013.4518.63
Research and Development20.7710.8510.058.176.727.789.9215.32
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-27.05-16.16-15.54-13.29-10.72-13.03-14.39-19.57
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.080.000.000.000.07
Net Income Before Taxes-25.20-15.15-14.77-12.59-10.06-12.46-13.70-18.68
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-25.20-15.15-14.77-12.59-10.06-12.46-13.70-18.68
Net Income From Continuing Operations-25.20-15.15-14.77-12.59-10.06-12.46-13.70-18.68
Net Income-25.20-15.15-14.77-12.59-10.06-12.46-13.70-18.68
EPS (Recurring)-0.14-0.12-0.13-0.12-0.14-0.24-0.27-0.37
EPS (Basic, Before Extraordinaries)-0.14-0.12-0.13-0.12-0.14-0.24-0.27-0.37
EPS (Diluted)-0.14-0.12-0.13-0.12-0.14-0.24-0.27-0.37
EBITDA-26.23-15.30-14.65-12.38-9.80-12.10-13.45-18.63
Non-Operating Income (Expense)1.841.000.780.780.660.570.690.96
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.302.732.421.611.781.891.721.85
Price To Sales Ratio-900.67721.67378.81172.5213.4710.5110.75
Gross Margin----8.30---
Operating Margin-----1,071.60---
Net Margin-----1,005.60---
Shares Outstanding101.83100.7375.5863.2863.1547.9047.9047.71
Market Capitalization493.94627.18460.16230.97150.9337.9345.3657.77

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments78.0672.99130.62161.28268.80335.4539.0960.38
Short Term Receivables0.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets4.416.2312.6023.3019.4610.193.355.26
Total Current Assets82.4779.22143.22184.58288.27345.6442.4465.63
Net Property, Plant & Equipment7.4511.6513.8020.319.943.002.442.50
Total Investments and Advances1.000.000.000.000.000.000.000.00
Deferred Tax Assets-1.20------
Other Assets0.100.182.540.430.380.350.090.02
Total Assets91.0392.25159.56205.32298.58348.9944.9768.16
Short Term Debt Incl. Current Port. of LT Debt0.840.900.800.700.000.000.000.00
Accounts Payable2.102.421.597.1710.011.753.052.05
Other Current Liabilities4.115.609.0717.0914.5715.0816.9318.80
Total Current Liabilities7.058.9211.4524.9624.5916.8319.9820.85
Long Term Debt1.582.513.414.200.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities-1.20------
Other Liabilities0.000.000.000.002.2122.2910.479.33
Total Liabilities8.6412.6214.8629.1726.8039.1330.4530.18
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.0049.0649.06
Common Equity82.3979.63144.71176.16271.79309.86-34.55-11.08
Total Shareholders Equity82.3979.63144.71176.16271.79309.8614.5237.98
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity82.3979.63144.71176.16271.79309.8614.5237.98
Total Liabilities & Stockholders Equity91.0392.25159.56205.32298.58348.9944.9768.16
Book Value Per Share1.301.673.064.166.427.42-0.83-0.27
Tangible Book Value Per Share1.301.673.064.166.427.42-0.83-0.27
Full-Time Employees4044751058559--
Price to Book Ratio2.550.602.690.491.337.06-37.91-
Return on Assets-53.26-59.89-47.85-40.46-13.89-18.58-42.40-
Return on Equity-60.25-67.23-54.41-45.52-15.46-22.57-91.36-
Return on Invested Capital-58.12-91.82-58.94-56.52-16.55-11.81-165.21-19.45
Quick Ratio11.708.8812.517.3911.7220.532.123.15
Current Ratio11.708.8812.517.3911.7220.532.123.15

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-67.72-48.81-75.41-87.30-101.94-44.97-36.60-23.98-7.39
Depreciation3.463.693.834.043.381.380.620.540.26
Other Funds (Non Cash)8.886.028.046.128.548.501.270.252.73
Funds from Operations-55.37-39.10-63.54-77.13-90.03-35.09-34.72-23.19-4.41
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital5.80-0.793.02-4.09-4.46-22.021.062.22-2.50
Cash from Operating Activities-49.57-39.88-60.52-81.23-94.50-57.12-33.66-20.98-6.90
Capital Expenditures-0.19-0.07-0.06-0.41-11.61-7.93-0.73-0.47-1.18
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.100.000.000.000.00
Purchase or Sale of Investments-89.18-7.82-8.45111.2760.95-2.52-145.59-3.12-28.73
Purchase of Investments-174.87-43.42-93.55-79.73-132.38-204.09-183.19-44.27-28.73
Sale Or Maturity of Investments85.6935.6085.10191.00193.32201.5737.5941.150.00
Other Uses0.000.000.000.000.000.000.000.00-0.01
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-89.37-7.89-8.51110.8649.44-10.44-146.32-3.59-29.93
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock158.4244.641.2448.670.171.93330.87-0.0635.15
Repurchase of Common Pref Stock0.000.00-0.020.000.000.000.000.000.00
Sale of Common Pref Stock158.4244.641.2548.670.171.93330.87-0.0635.15
Proceedsfrom Stock Options0.000.000.0048.170.000.00330.64-0.0635.15
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.27-0.07-0.45-0.050.000.000.000.000.00
Other Financing Activities Uses-0.27-0.07-0.45-0.050.000.000.000.000.00
Cash from Financing Activities158.1544.570.7948.620.171.93330.87-0.0635.15
Net Change in Cash19.21-3.19-68.2478.25-44.89-65.63150.88-24.63-1.68
Free Cash Flow-49.76-39.95-60.57-81.64-106.11-65.04-34.39-21.45-8.08
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments196.31208.3090.4278.0686.1350.47
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets5.294.973.334.414.594.21
Total Current Assets201.60213.2793.7582.4790.7254.67
Net Property, Plant & Equipment3.634.515.357.457.057.95
Total Investments and Advances1.001.001.001.000.000.00
Other Assets1.741.882.020.102.561.75
Total Assets207.97220.67102.1291.03100.3364.37
Short Term Debt Incl. Current Port. of LT Debt0.900.870.850.840.870.96
Accounts Payable3.923.941.252.101.160.47
Other Current Liabilities7.942.922.144.113.303.90
Total Current Liabilities12.767.734.257.055.345.34
Long Term Debt1.551.802.041.581.762.02
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities14.319.536.298.647.097.35
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity193.66211.1495.8382.3993.2457.02
Total Shareholders Equity193.66211.1495.8382.3993.2457.02
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity193.66211.1495.8382.3993.2457.02
Total Liabilities & Stockholders Equity207.97220.67102.1291.03100.3364.37
Book Value Per Share1.902.101.271.301.481.19
Tangible Book Value Per Share1.902.101.271.301.481.19
Full-Time Employees---40--
Price to Book Ratio2.555.474.942.472.010.56
Return on Assets-43.93-36.88-55.64-53.26-51.77-63.75
Return on Equity-47.20-39.21-61.04-60.25-57.84-73.39
Return on Invested Capital-12.91-7.12-15.09-15.00-10.59-21.10
Quick Ratio15.8027.5922.0611.7017.0010.25
Current Ratio15.8027.5922.0611.7017.0010.25

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-25.20-15.15-14.77-12.59-10.06-12.46
Depreciation0.810.850.890.910.920.93
Other Funds (Non Cash)2.911.992.501.490.692.01
Funds from Operations-21.48-12.31-11.38-10.20-8.45-9.52
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.012.13-2.051.71-0.48-0.92
Cash from Operating Activities-17.47-10.19-13.42-8.49-8.93-10.43
Capital Expenditures-0.05-0.140.000.00-0.070.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments11.78-144.8123.8520.00-43.420.00
Purchase of Investments-30.00-144.80-0.070.00-43.420.00
Sale Or Maturity of Investments41.78-0.0023.9120.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities11.73-144.9523.8520.00-43.490.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock4.20128.0226.070.1344.500.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.20128.0226.070.1344.500.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.01-0.260.000.000.00
Other Financing Activities Uses0.00-0.01-0.260.000.000.00
Cash from Financing Activities4.20128.0125.800.1344.500.00
Net Change in Cash-1.54-27.1236.2311.64-7.92-10.43
Free Cash Flow-17.52-10.33-13.42-8.49-9.00-

Revenue breakdown

Collaboration2024: 5.72M
License2025: 1.00M
United States2024: 5.72M 2025: 1.00M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3012.28%10.7M87.5M1.14M
2026-10-1512.11%10.4M86.2M1.20M
2026-09-3012.70%10.9M86.2M1.18M
2026-09-157.90%6.8M86.2M1.24M
2026-08-316.58%5.6M84.7M1.34M
2026-08-147.10%6.0M84.7M1.31M
2026-07-318.00%6.4M80.0M1.25M
2026-07-159.76%7.8M80.0M1.11M
2026-06-307.59%5.9M78.1M961.34K
2026-06-153.25%2.5M78.1M699.28K
2026-05-291.75%1.1M65.7M609.15K
2026-05-152.01%1.3M65.8M576.28K
2026-04-302.17%1.4M65.3M530.23K
2026-04-152.08%1.3M64.4M624.09K
2026-03-312.61%1.5M56.1M679.05K
2026-03-132.81%1.6M56.1M643.02K
2026-02-273.23%1.6M49.6M567.72K
2026-02-133.87%1.9M49.6M538.37K
2026-01-304.54%2.3M49.6M502.57K
2026-01-154.43%2.2M49.6M371.05K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.001.606.500.000.0000.000.000.0000.0000.000
call2.000.555.400.0023.3930.000.000.982-0.0450.000
call3.000.004.400.0019.1640.000.000.851-0.0470.002
call4.000.003.500.0012.7430.000.000.754-0.0380.002
call5.000.002.800.0010.6080.000.000.789-0.1270.002
call6.000.000.950.354.2681,1620.000.516-0.0740.003
call7.000.002.550.1510.2862.000.000.734-0.1370.003
call8.000.002.550.6010.7902.000.000.726-0.1460.003
call9.000.002.550.0011.2140.000.000.720-0.1530.003
call10.000.002.550.0011.5780.000.000.715-0.1590.003
call11.000.002.550.0011.8970.000.000.711-0.1650.003
call12.000.002.550.0012.1810.000.000.707-0.1700.003
put1.000.002.550.006.4480.000.00-0.018-0.0130.000
put2.000.002.550.000.0000.000.000.0000.0000.000
put3.000.002.550.004.4040.000.00-0.143-0.0430.002
put4.000.002.550.0012.3630.000.00-0.141-0.1160.002
put5.000.150.600.001.0260.000.00-0.320-0.0950.003
put6.000.003.500.659.4678050.00-0.484-0.0730.003
put7.000.004.500.0010.9420.000.00-0.522-0.0830.003
put8.000.555.400.0010.2350.000.00-0.546-0.0940.003
put9.001.606.500.0011.1100.000.00-0.563-0.1030.003
put10.002.607.500.0011.5030.000.00-0.575-0.1090.003
put11.003.508.400.0011.4630.000.00-0.585-0.1140.003
put12.004.509.400.0011.7700.000.00-0.593-0.1190.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-27SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-11S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-17SCHEDULE 13D/ASEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-02144Filing for proposed sale of securities under Rule 144.SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-06-30144Filing for proposed sale of securities under Rule 144.SEC
2026-06-17SCHEDULE 13GSEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-15SCHEDULE 13D/ASEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-118-KCurrent report2026-06-09SEC
2026-06-11424B5SEC
2026-06-11SCHEDULE 13D/ASEC
2026-06-09424B5SEC
2026-06-098-KCurrent report2026-06-08SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-05-29SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-07003.58K2
2026-06250.00K1375.72K2
2026-0500212.54K2
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
T. Rowe Price Investment Management, Inc.14.86%
ADAGE CAPITAL PARTNERS GP, L.L.C.8.99%
Redmile Group, LLC7.63%
ORBIMED ADVISORS LLC6.98%
Prosight Management, LP6.59%
BlackRock, Inc.4.36%
Frazier Life Sciences Management, L.P.4.15%
NEXTBio Capital Management LP4.12%
Deep Track Capital, LP4.10%
VANGUARD CAPITAL MANAGEMENT LLC3.55%

Funds

Fund% owned
T. Rowe Price Small-Cap Value Fund, Inc.3.95%
T. Rowe Price Small-Cap Stock Fund, Inc.3.45%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.62%
T. Rowe Price Health Sciences Fund, Inc.2.20%
T. Rowe Price Institutional Small-Cap Stock Fund1.86%
iShares Russell 2000 ETF1.70%
abrdn Life Sciences Investors1.56%
VANGUARD EXTENDED MARKET INDEX FUND0.85%
Fidelity Small Cap Index Fund0.74%
iShares Russell 2000 Growth ETF0.56%

OakChart. STTK. Cached 15 minutes.